Musculoskeletal Outcomes of Glucagon-Like Peptide-1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) just scored more points for the peptide research playbook. A massive cohort study out of Taipei Medical University dug into how these compounds stack up against other anti-obesity agents in nondiabetic adults. The results: better musculoskeletal outcomes nearly across the board.
Obesity (Silver Spring)
by Wu JS, Lin LY, Sun JW et al.
“Musculoskeletal Outcomes of Glucagon-Like Peptide-1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults. Wu JS(1), Lin LY(1)(2), Sun JW(1), Yu WT(1), Yuliani FS(3), Lin SH(4)(5). Author information: (1)School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. (2)Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan. (3)Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia. (4)School of Nutrition, College of Nutrition, Taipei Medical University, Taipei, Taiwan. (5)School of Food Safety, College of Nutrition, Taipei Medical University, Taipei, Taiwan. OBJECTIVE: This study aimed to evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications. METHODS: This retrospective cohort study included deidentified TriNetX data on ≥ 50-year-old nondiabetic adults with obesity. After 1:1 propensity score matching on demographic, clinical, and laboratory covariates, 18,062 GLP-1 RA users were compared with non-GLP-1 medication users. The primary outcome was incident osteoporosis; secondary outcomes included major osteoporotic fractures, cervical and thoracolumbar disc disorders, and osteoarthritis. RESULTS: GLP-1 RA use was associated with lower risks of osteoporosis (relative risk [RR] 0.48; 95% CI, 0.43-0.52; number needed to treat [NNT] = 28), major osteoporotic fractures (RR 0.15; 95% CI, 0.11-0.22; NNT = 88), cervical disc degeneration (RR 0.34; 95% CI, 0.28-0.41; NNT = 63), thoracolumbar disc disease (RR 0.36; 95% CI, 0.33-0.40; NNT = 20), and osteoarthritis (RR 0.45; 95% CI, 0.43-0.48; NNT = 9). Protective associations were consistent across age, sex, BMI, and drug subtype subgroups and remained robust in sensitivity analyses. CONCLUSIONS: GLP-1 RA use was associated with favorable musculoskeletal outcomes, including lower risks of osteoporosis and fractures, in nondiabetic adults with obesity compared with other obesity medications. © 2026 The Author(s). Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.”
Researchers sifted through data from over 18,000 GLP-1 RA users, all obese, all over 50, and none with diabetes. After matching them with a group taking other obesity meds, the team compared rates of osteoporosis, fractures, and joint issues.
Key takeaway: GLP-1 RAs were linked with a much lower risk of bone loss and joint degeneration. The numbers are hard to ignore:
Osteoporosis risk was cut by more than half (RR 0.48)
Major osteoporotic fractures? Down by 85% (RR 0.15)
Cervical and thoracolumbar disc degeneration dropped by two-thirds
Osteoarthritis rates slashed significantly (RR 0.45)
The protective effect held steady across age, sex, BMI, and drug subtypes. No matter how you slice the data, these peptide-based compounds came out ahead. Researchers even ran sensitivity analyses to make sure the findings weren’t a fluke—same result.
What’s going on? The GLP-1 pathway keeps getting more interesting. There’s already buzz around metabolic effects, but these outcomes underline how peptide research keeps opening new doors for musculoskeletal health, too.
For anyone mapping out peptide projects, this is another reason to keep a close eye on GLP-1 RAs and related research compounds. Check the peptide research index for more studies and hit up the vendor directory if you’re planning your next experiment. Peptides are still delivering surprises—this study just added a few more.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.